RDY 6-K
Dr Reddys Laboratories Ltd (RDY)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
October, 2024
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
| Exhibit Number | Description of Exhibits |
|---|---|
| 99.1 | Press Release dated October 28, 2024 |
| 2 |
| --- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| DR. REDDY’S LABORATORIES LIMITED<br><br> <br>(Registrant) | |||
|---|---|---|---|
| Date: October 28, 2024 | By: | /s/ K Randhir Singh | |
| Name: | K Randhir Singh | ||
| Title: | Company Secretary |
| 3 |
| --- |
Exhibit 99.1
| Dr. Reddy’s Laboratories Ltd.<br><br> <br>8-2-337, Road No. 3, Banjara Hills,<br><br> <br>Hyderabad - 500 034, Telangana,<br><br> <br>India.<br><br> <br>CIN : L85195TG1984PLC004507<br><br> <br>****<br><br> <br>Tel : +91 40 4900 2900<br><br> <br>Fax : +91 40 4900 2999<br><br> <br>Email : [email protected]<br><br> <br>www.drreddys.com |
|---|
October 28, 2024
National Stock Exchange of India Ltd. (Stock Code: DRREDDY-EQ)
BSE Limited (Stock Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd. (Stock Code: DRREDDY)
Dear Sir/Madam,
Sub: Press Release
Please find enclosed a Press Release on “Dr.Reddy's launches Elobixibat (BixiBat®) a first-in-class drug to treat chronic constipation in India”.
This is for your information and record.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer & Head-CSR
Encl: As above
| DR. REDDY'S LABORATORIES LTD.<br><br> <br>8-2-337, Road No. 3, Banjara Hills,<br><br> <br>Hyderabad - 500034. Telangana, India. | CONTACT | |
|---|---|---|
| Investor relationS | Media relationS | |
| RICHA PERIWAL<br><br> <br>[email protected] | USHA IYER<br><br> <br>[email protected] |
Dr. Reddy's launches Elobixibat (BixiBat®) afirst-in-class drug to treat chronic constipation in India
Becomes the first company to bring this first-in-classdrug to patients in India
Hyderabad India; October 28, 2024 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), announced the launch of Elobixibat, a first-in-class drug to treat chronic constipation, in India. Dr. Reddy’s will market Elobixibat under the brand name BixiBat® in India.
The launch follows approval granted to Dr. Reddy's by the Central Drugs Standard Control Organisation (CDSCO) subsequent to submission of the company's successful Phase-3 clinical trial to the Subject Expert Committee of the CDSCO. Dr. Reddy’s is the first company to receive approval for and launch Elobixibat in India.
Elobixibat is a breakthrough drug approved for the treatment of chronic constipation. It acts by inhibiting the reabsorption of bile acids from ileum, thus increasing their concentration in the colonic lumen, leading to increased bowel movements due to stimulation of both colonic motility and fluid secretion irrespective of the transit speed.
M.V. Ramana, Chief Executive Officer, Branded Markets(India and Emerging Markets), Dr. Reddy’s, said: “The launch of this first-in-class drug is the latest in our continuedefforts to bring novel molecules to patients in India. With over three decades of expertise and leadership in the gastrointestinal segmentin India through trusted products such as Omez®, Razo™, Econorm®, and Redotil™, this latest offering will help usaddress unmet patient needs and further improve quality of life. The clinical studies for BixiBat® have demonstrated significantlybetter and promising outcomes, making it a breakthrough drug in the management of chronic constipation and enhancing the current standardof care for its treatment in India.”
Studies in Asia show that close to 40% of patients suffering from chronic constipation are dissatisfied with current treatment options^1^. Around 12% of the population in India suffers from symptoms of constipation, heavily impacting their quality of life^2^.
| ^1^ | Xiong L. J Gastroenterol Hepatol 2017;32:1450-1456 |
|---|---|
| ^2^ | Ghoshal UC, et al. Indian J Gastroenterol. 2018;37(6):526–544 |
| --- | --- |
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of ‘Good Health Can’t Wait’, we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers’, products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2024. The company assumes no obligation to update any information contained herein.